Jan 09, 2023 / 04:15PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. Welcome. I'm Jess Fye. I'm a large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference this morning with Vertex. There's going to be a Q&A session right in this room after the company's presentation, so no need to switch rooms. There's going to be mic runners. So if you have a question, you want to raise your hand, you can do that. Alternatively, you can use the portal to fire me questions to an iPad up here, and I can ask them for you or you can just listen to my questions. But without any further ado, let me pass it over to the CEO of Vertex, Reshma Kewalramani, for the presentation.
Reshma Kewalramani - Vertex Pharmaceuticals Incorporated - CEO, President & Director
Well, good morning, everybody. Jess, thank you so much, and thank you to JPMorgan for hosting this. It is nice to be back in San Francisco in person and to do this live. Some housekeeping notes to start with. This slide has our safe harbor statement
Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers